(Q38936986)

7 September 2017

In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells (English)

1 reference

7 September 2017

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Mehmet K Tur

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Judith Niesen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hannes Brehm

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Christoph Stein

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Nina Berges

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Alessa Pardo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Rainer Fischer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Andre Ten Haaf

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Stefan Gattenlöhner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

30 November 2014

1 reference

Journal of Cancer Research and Clinical Oncology

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1049-1061

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25433506%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00432-014-1884-z

9 June 2020

exact match

0 references

cites work

Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

scFv antibody: principles and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Ligand-targeted therapeutics in anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Immunotoxins: the role of the toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

What is new in the biology and treatment of pediatric rhabdomyosarcoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Recombinant Toxins for Cancer Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Recombinant toxins as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Emerging combination therapies to overcome resistance in EGFR-driven tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Targeting the ERBB family in cancer: couples therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Immunotoxins for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Advances in therapy for pediatric sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Rhabdomyosarcomas: an overview on the experimental animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1884-Z

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms

21 January 2018

1 reference

12 December 2020

Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.

1 reference

12 December 2020

The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.

1 reference

12 December 2020

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor

1 reference

12 December 2020

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

1 reference

12 December 2020

Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro

1 reference

12 December 2020

Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells

1 reference

12 December 2020

Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family

1 reference

12 December 2020

HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells

1 reference

12 December 2020

Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.

1 reference

12 December 2020

Clonal analysis of a human antimouse antibody (HAMA) response

1 reference

12 December 2020

Immunotoxins for targeted cancer therapy

1 reference

12 December 2020

Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma

1 reference

12 December 2020

Rhabdomyosarcoma in adolescents

1 reference

12 December 2020

Technology evaluation: BL22, NCI.

1 reference

12 December 2020

Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.

1 reference

12 December 2020

Pharmacokinetics and biodistribution of genetically-engineered antibodies

1 reference

12 December 2020

Molecular classification of soft tissue sarcomas and its clinical applications

1 reference

12 December 2020

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

12 December 2020

The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice

1 reference

12 December 2020

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer

1 reference

12 December 2020

Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

1 reference

12 December 2020

Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry

1 reference

12 December 2020